Bictegravir, also known as GS-9883, is a potent, unboosted, once-Daily HIV-1 Integrase Strand Transfer Inhibitor (INSTI) (IC50 - 1.6 nM) with improved pharmacokinetics and in vitro resistance profile. Bictegravir, as part of a fixed-dose combination product containing bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF), is in Phase III development.
Phull, Manjinder Singh; Rao, Dharmaraj Ramachandra; Birari, Dilip Ramdas. Process for the preparation of bictegravir and intermediate thereof. Assignee Cipla Limited, India. WO 2018229798. (2018).
